Vaisala Group
9.9.2025 17:30:00 CEST | Globenewswire | Press release
Vaisala Corporation: Share Repurchase 9.9.2025
Vaisala Corporation: Share Repurchase 9.9.2025
| VAISALA CORPORATION | STOCK EXCHANGE RELEASE 9.9.2025 | |
| Vaisala Corporation: Share Repurchase 9.9.2025 | ||
| In the Helsinki Stock Exchange | ||
| Trade date | 9.9.2025 | |
| Bourse trade | Buy | |
| Share | VAIAS | |
| Amount | 3 502 | Shares |
| Average price/ share | 45,6755 | EUR |
| Total cost | 159 955,60 | EUR |
| Vaisala Corporation now holds a total of 180 290 shares | ||
| including the shares repurchased on 9.9.2025 | ||
| The share buybacks are executed in compliance with Regulation | ||
| No. 596/2014 of the European Parliament and Council (MAR) Article 5 | ||
| and the Commission Delegated Regulation (EU) 2016/1052. | ||
| On behalf of Vaisala Corporation | ||
| Nordea Bank Oyj | ||
| Sami Huttunen | Ilari Isomäki | |
More information:
Niina Ala-Luopa
+358 400 728 957, ir@vaisala.com
Distribution:
Nasdaq Helsinki
Key media
vaisala.com
Vaisala is a global leader in measurement instruments and intelligence for climate action. We equip our customers with devices and data to improve resource efficiency, drive energy transition, and care for the safety and well-being of people and societies worldwide. With almost 90 years of innovation and expertise, we employ a team of close to 2,500 experts committed to taking every measure for the planet. Vaisala series A shares are listed on the Nasdaq Helsinki stock exchange. www.vaisala.com
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S25.10.2026 12:00:00 CET | Press release
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
Genmab A/S24.10.2026 13:00:00 CEST | Press release
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
ASYAD24.10.2026 12:47:36 CEST | Press release
Asyad Group to Host Muscat Maritime Resilience Forum to Strengthen Global Trade Networks
King Faisal Specialist Hospital & Research Centre24.10.2026 11:00:00 CEST | Press release
KFSH Extends Emergency Access Through Virtual Care and Specialist Coordination
Orion Oyj24.10.2026 08:35:00 CEST | Press release
Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom